- Revenue Cycle Management
- COVID-19
- Reimbursement
- Diabetes Awareness Month
- Risk Management
- Patient Retention
- Staffing
- Medical Economics® 100th Anniversary
- Coding and documentation
- Business of Endocrinology
- Telehealth
- Physicians Financial News
- Cybersecurity
- Cardiovascular Clinical Consult
- Locum Tenens, brought to you by LocumLife®
- Weight Management
- Business of Women's Health
- Practice Efficiency
- Finance and Wealth
- EHRs
- Remote Patient Monitoring
- Sponsored Webinars
- Medical Technology
- Billing and collections
- Acute Pain Management
- Exclusive Content
- Value-based Care
- Business of Pediatrics
- Concierge Medicine 2.0 by Castle Connolly Private Health Partners
- Practice Growth
- Concierge Medicine
- Business of Cardiology
- Implementing the Topcon Ocular Telehealth Platform
- Malpractice
- Influenza
- Sexual Health
- Chronic Conditions
- Technology
- Legal and Policy
- Money
- Opinion
- Vaccines
- Practice Management
- Patient Relations
- Careers
Combination COVID-19 and flu test gets EUA
The SpeedySwab Covid + FLU A&B Self-Test has received emergency use authorization for over the counter and point of care applications.
© Tada Images - stock.adobe.com
A new 3-in-1 test for COVID-19 and FLU A and B has received emergency use authorization (EUA) from the Food and Drug Administration.
The advanced SpeedySwab™ Covid + FLU A&B Self-Test for over the counter and point of care use was developed by Watmind USA in partnership with the National Institutes of Health’s (NIH) Rapid Acceleration of Diagnostics Independent Assessment Program, according to a news release.
The test is designed help symptomatic patients over the age of 2 to quickly identify whether they are suffering from COVID-19, Influenza A, or Influenza B. Through a user-friendly, step-by-step process the uses state-of-the art Lateral Flow Assay (LFA) technology.
"Receiving the EUA for our SpeedySwab test marks a significant milestone in our commitment to advancing public health," said Dan Davis, CEO of Watmind USA, says in the release. "As we navigate the ongoing challenges of COVID-19 and influenza A&B strains, our goal is to provide accessible and rapid at-home testing solutions that empower individuals to proactively manage their health from the comfort of their homes, while minimizing the spread of such diseases. Watmind USA is proud to support critical public health initiatives."
The question of whether a patient was suffering from COVID-19 one of the forms of Influenza was the cause of anxiety early in the COVID-19 pandemic. In recent years the NIH has expanded efforts to treat the viruses at home.
In December, NIH expanded the Home Test to Treat Program “an entirely virtual community health program” with free at-home rapid tests, telehealth sessions, and treatments.
NIH announced it as “the first public health program that includes home testing technology at such a scale for both COVID-19 and flu.”
The program seeks adult enrollees who are uninsured or underinsured, on Medicare, Medicaid, or receive care through the U.S. Department of Veterans Affairs or Indian Health Services. Patients will use the LUCIRA by Pfizer COVIC-19 & Flu Home Test, the first approved by the U.S. Food and Drug Administration to detect both viruses in single test at home.
